Goldman Sachs Upgrades Boston Scientific (BSX) to Neutral
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $49.80 -4.25%
Rating Summary:
33 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 20
Rating Summary:
33 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 20
Join SI Premium – FREE
Goldman Sachs upgraded Boston Scientific (NYSE: BSX) from Sell to Neutral and raised their price target from $6.50 to $7.
The firm said they no longer see material downside to consensus estimates, and the stock is one of the worst performing S&P healthcare so far this year.
For more ratings news on Boston Scientific click here and for the rating history of Boston Scientific click here.
Shares of Boston Scientific closed at $6.67 yesterday.
The firm said they no longer see material downside to consensus estimates, and the stock is one of the worst performing S&P healthcare so far this year.
For more ratings news on Boston Scientific click here and for the rating history of Boston Scientific click here.
Shares of Boston Scientific closed at $6.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
- BofA Securities Upgrades Moderna (MRNA) to Neutral
- Morgan Stanley Upgrades Honeywell Aerospace Inc (HONA) to Overweight
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman Sachs, Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
